Optimizing Early Breast Cancer Outcomes in the Community Setting: An Expert Review of Emerging Therapies and Evolving Standards of Care in HR+/HER2- Disease

Supported through an independent educational grant from Lilly.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners:
Elizabeth Dow-Hillgartner, PharmD, BCPS, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
Jennifer A. McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Sara Tolaney, MD, MPH–has disclosed that she is a consultant for 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, BeyondSpring Pharmaceuticals, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Genentech/Roche, Immunomedics/Gilead, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Puma, Sanofi, and Seattle Genetics. She receives grant/research funding from Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics.

Presenters:
Elizabeth Dow-Hillgartner, PharmD, BCPS, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
Hope S. Rugo, MD–has disclosed that she receives grant/research support from AstraZeneca, Ayala, Astellas, Boehringer Ingelheim, Daiichi, Gilead, Lilly, Macrogenics, Merck, Novartis, Pfizer, Polyphor, Roche, and Seattle Genetics.
Sara Tolaney, MD, MPH–has disclosed that she is a consultant for 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, BeyondSpring Pharmaceuticals, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Genentech/Roche, Immunomedics/Gilead, Merck, Mersana Therapeutics, Nanostring, Nektar, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Puma, Sanofi, and Seattle Genetics. She receives grant/research funding from Bristol-Myers Squibb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics.

Peer Reviewer:
Katherine Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.